Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 12/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646645 | 1.00 | MCL1 (0.42) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL12589812 | 1.00 | MCL1 (0.42) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL13481730 | 1.00 | MCL1 (0.42) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL13481692 | 0.89 | P2RX3 (0.51) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL1198567 | 0.89 | P2RX3 (0.51) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL12589826 | 0.89 | P2RX3 (0.51) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL13106875 | 0.89 | P2RX3 (0.51) | MCL1P2RX3EPHX2SLC6A4GRM5 | |
| SCHEMBL23452261 | 0.87 | MCL1 (0.51) | MCL1P2RX3UCHL1 | |
| SCHEMBL9544995 | 0.87 | MCL1 (0.51) | MCL1P2RX3UCHL1 | |
| SCHEMBL6842708 | 0.87 | MCL1 (0.51) | MCL1P2RX3UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| EP-2196201-A2 | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms | Warner-Lambert Company LLC (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7432299-B2 | Method of treatment for sexual dysfunction | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432299-B2 | Method of treatment for sexual dysfunction | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20040180958-A1 | Method of treatment | PFIZER PRODUCTS INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040176456-A1 | Method of treatment for sexual dysfunction | TAYLOR CHARLES PRICE (US) | 2004-09-09 | — | — | US | disclosed |
| WO-2004054560-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176456-A1 | Method of treatment for sexual dysfunction | SHBG, CHRND, ADRB2 | MCL1 4867/4885P2RX3 420/4885EPHX2 2096/4885 |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | GABRB2, GABRB3, GABRB1 | MCL1 4873/4885P2RX3 795/4885EPHX2 2707/4885 |
| US-20040180958-A1 | Method of treatment | BPHL, ADRA2B, ADRB2 | MCL1 4876/4885P2RX3 1863/4885EPHX2 1598/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | MCL1 3022/4885P2RX3 22/4885EPHX2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.